药物治疗动脉粥样硬化新途径——抗炎作用

越来越多的实验证据和临床资料表明 ,炎症反应贯穿了动脉粥样硬化发生和发展的整个过程。炎症可以激活单核细胞和刺激内皮细胞产生促炎因子 ,进而刺激血管平滑肌细胞迁移、增殖 ,炎症继续发展 ,细胞释放的水解酶、细胞因子等进一步加重损伤 ,最终形成斑块。因此 ,根据这一新的发病机制 ,通过抗炎途径治疗动脉粥样硬化已引起人们的极大关注。该文对药物通过调节C反应蛋白、CD4 0 CD4 0L、感染和NF κB抗动脉粥样硬化的研究进展作一综述

New pathway of atherosclerotic drug therapy--anti-inflammatory effect

There are increasing experimental evidences and clinical data showing that inflammatory reaction plays an important role in the production and development of atherosclerosis. Inflammatory process promotes the production and release of inflammatory factors by activation of monocytes and stimulation of endothelial cells, which stimulate the migration and proliferation of vascular smooth muscle cells. Hydrolases and cytokines are released from the activated and stimulated cells to increase local lesion and form atherosclerotic plaque with the development of inflammation. So, on the basis of the new pathogenesis of atherosclerosis,scientists try to interfere with atherosclerosis by anti-inflammatory pathway. This paper reviews the progress of drugs against atherosclerosis by the modulation of C reaction protein ,CD40-CD40L,infection and NF-κB.